Neuroscientific Biopharmaceuticals Ltd. ( (AU:NSB) ) just unveiled an announcement.
NeuroScientific Biopharmaceuticals Ltd has announced preparations for two IND-enabling pre-clinical studies for EmtinB, targeting advanced glaucoma. Additionally, the company is acquiring StemSmart technology from Isopogen WA, which involves the use of mesenchymal stromal cells (MSC) derived from adult human donor bone marrow to treat various serious conditions. This acquisition positions NeuroScientific to expand its offerings in the cellular medicine market, with potential impacts on markets such as Crohn’s disease and organ transplant immuno-suppressants. The company has also secured $3.5 million in funding to support these initiatives.
More about Neuroscientific Biopharmaceuticals Ltd.
NeuroScientific Biopharmaceuticals Ltd is a company operating in the biopharmaceutical industry, focusing on developing innovative therapies. The company is involved in the research and development of treatments for neurological conditions, with a market focus on advanced glaucoma and cellular medicines.
YTD Price Performance: 70.0%
Average Trading Volume: 386,360
Technical Sentiment Signal: Sell
Current Market Cap: A$7.37M
For an in-depth examination of NSB stock, go to TipRanks’ Stock Analysis page.